Clinical Trial

Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart Failure

Study acronym: POSTBIO-HF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Several surrogate biomarkers including natriuretic peptide(NP), and growth differentiation factor-15(GDF-15) and ST2 has prognostic significance in heart failure(HF), and reductions in its value may predict clinical improvement. However, there are limited data regarding the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated heart failure. The purpose of this study is to evaluate the prognostic value of short-term follow-up surrogate biomarkers for predicting prognosis of hospitalized patients with acute decompensated heart failure.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-16; most recent amendment 2024-09-06.
Status change: Not Yet Recruiting → Recruiting 2021-05-12
Trial Details
NCT Number NCT04437628
Lead Sponsor Wonju Severance Christian Hospital
Collaborators: Roche diagnostics Korea
Conditions Heart Failure
Enrollment 1,500 participants
Start Date 2021-02-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19